InNexus Biotechnology, Inc. (IXSBF)の価格はいくらですか

InNexus Biotechnology, Inc. (IXSBF)の価格は$0.0001です

InNexus Biotechnology, Inc. (IXSBF)の時価総額は何ですか

InNexus Biotechnology, Inc. (IXSBF)の時価総額は$12.63Kです

InNexus Biotechnology, Inc.（IXSBF）営業利益率

InNexus Biotechnology, Inc. is a development-stage company dedicated to advancing and commercializing monoclonal antibodies. Its efforts are underpinned by its proprietary Dynamic Cross Linking (DXL) technology. This DXL platform is designed to boost the therapeutic efficacy of conventional monoclonal antibody treatments by strengthening their binding to target antigens, amplifying their effector functions, and endowing them with novel properties. InNexus's development portfolio features several investigational therapies: DXL625: A monoclonal antibody currently in late-stage pre-clinical development, engineered for superior binding kinetics and enhanced effector functions, intended for treating B-cell non-Hodgkin's lymphoma (NHL). DXLr120: A recombinant DXL anti-CD20 antibody also being developed for B-cell NHL. DXL702: A monoclonal antibody targeting metastatic breast cancer. DXL1218: An agent designed to target the epidermal growth factor receptor (EGFR), an antigen frequently overexpressed in metastatic colorectal cancer and squamous cell carcinomas of the head and neck. The company also maintains strategic partnerships with XERIS Pharmaceuticals, Genhelix, Evogenix, Affimed, and Corixa. InNexus Biotechnology, Inc. is based in Vancouver, Canada.

年	営業利益率	変化
提供された日付のデータは十分ではありません。

年

営業利益率

変化

提供された日付のデータは十分ではありません。

企業	営業利益率	営業利益率の差	国
Royalty Pharma plc RPRX.US	67.93%	-	US
Swedish Orphan Biovitrum AB SOBI.ST	0.00%	-	SE
Ipsen S.A. IPN.PA	0.00%	-	FR
Recordati Industria Chimica e Farmaceutica S.p.A. REC.MI	0.00%	-	IT
Corcept Therapeutics Incorporated CORT.US	0.77%	-	US

企業

営業利益率

営業利益率の差

国